The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | D | Dermatologicals | |
| 2 | D11 | Other dermatological preparations | |
| 3 | D11A | Other dermatological preparations | |
| 4 | D11AH | Agents for dermatitis, excluding corticosteroids | |
| 5 | D11AH08 |
| Active Ingredient | Description | |
|---|---|---|
| Abrocitinib |
Abrocitinib is a Janus kinase (JAK)1 inhibitor. JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of haematopoiesis and immune cell function. JAKs phosphorylate and activate Signal Transducers and Activators of Transcription (STATs) which modulate intracellular activity including gene expression. Inhibition of JAK1 modulates the signalling pathways by preventing the phosphorylation and activation of STATs. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| CIBINQO Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
